---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-008625"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:15:18.867042+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences reports Q4 2022 net loss of $9.2M, no revenue; shifts focus to atrial fibrillation

## Summary
- Q4 2022 GAAP net loss of $9.2M vs $15.4M in Q4 2021; non-GAAP net loss $8.1M.
- No revenue in Q4 2022; full-year 2022 revenue $0.7M from discontinued dermatology.
- Cash, cash equivalents and investments $61.1M at Dec 31, 2022; cash burn reduced to $8.0M in Q4.
- Company focuses on nsPFA cardiac ablation for atrial fibrillation; FDA pre-submission for clamp planned in Q2 2023.
- Appointed Manmeet S. Soni as Lead Independent Director with $80,000 annual fee.

## SEC filing metadata
- accession: 0001437749-23-008625
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774923008625/0001437749-23-008625-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774923008625/plse20230329_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-008625
- JSON: https://secwatch.observer/filing/0001437749-23-008625.json
- Plain text: https://secwatch.observer/filing/0001437749-23-008625.txt

## Key facts
- Earnings Releases
  PULSE BIOSCIENCES, INC. reported financial results for the fourth quarter and full year ended December 31, 2022.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: Pulse Biosciences, Inc. (the “Company”) announced its financial and operational results for the fiscal quarter and full year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1625101/000143774923008625/0001437749-23-008625-index.htm
- Executive change
  Manmeet S. Soni was appointed as Lead Independent Director at PULSE BIOSCIENCES, INC..
  - Action: appointed
  - Role: Lead Independent Director
  source text: On March 28, 2023, the Company's Board of Directors appointed Manmeet S. Soni to the newly created position of Lead Independent Director of the Board of Directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1625101/000143774923008625/0001437749-23-008625-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.